Perspective: The problem of non-O157:H7 shiga toxin (verocytotoxin)- producing Escherichia coli

Journal of Infectious Diseases

Volumn 174, Issue 5, 1996, Pages 1136-1139

  Tarr, Phillip I ^a   Neill, Marguerite A ^b  

^a SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

VEROTOXIN;

BACTERIAL VIRULENCE; BACTERIUM IDENTIFICATION; DIARRHEA; DISEASE SEVERITY; ENTEROBACTER INFECTION; FECES ANALYSIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; STRAIN DIFFERENCE; TOXIN SYNTHESIS;

EID: 0029859196     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/174.5.1136     Document Type: Short Survey

References (14)

1. Tarr PI. Escherichia coli O157:H7: clinical, diagnostic, and epidemiological aspects of human infection. Clin Infect Dis 1995;20:1-8.
2. Boyce TG, Swerdlow DL, Griffin PM. Escherichia coli O157:H7 and the hemolytic-uremic syndrome. N Engl J Med 1995;333:364-8.
3. Calderwood SB, Acheson DWK, Keusch GT, et al. Proposed new nomenclature for Shiga-like toxin (verotoxin) family. ASM News 1996;62:118-9.
4. Karmali MA, Lingwood CA, Petric M, Brunton J, Gyles C. Maintaining the existing phenotype nomenclatures for E. coli cytotoxins. ASM News 1996;62:167-9.
5. Wells JG, Davis BR, Wachsmuth IK, et al. Laboratory investigation of hemorrhagic colitis outbreaks associated with a rare Escherichia coli serotype. J Clin Microbiol 1983;18:512-20.
6. March SB, Ratnam S. Sorbitol-MacConkey medium for detection of Escherichia coli O157:H7 associated with hemorrhagic colitis. J Clin Microbiol 1986;23:869-72.
7. Bajak J, Bauer P, Campbell D, et al. Avoidance of economic entropy in culturing Escherichia coli O157:H7 [abstract]. In: Abstracts of the 93rd general meeting of the American Society for Microbiology (Washington, DC). Washington, DC: ASM, 1993:52.
8. Centers for Disease Control and Prevention. Outbreak of acute gastroenteritis attributable to Escherichia coli serotype O104:1121 - Helena, Montana, 1994. JAMA 1995;274:529-30.
9. Ojeda A, Prado V, Martinez J, et al. Sorbitol-negative phenotype among enterohemorrhagic Escherichia coli strains of different serotypes and from different sources. J Clin Microbiol 1995;33:2199-201.
10. Gunzer F, Bohm H, Russmann H, Bitzan M, Aleksic S, Karch H. Molecular detection of sorbitol-fermenting Escherichia coli O157 in patients with hemolytic-uremic syndrome. J Clin Microbiol 1992;30:1807-10.
11. Ludwig K, Bitzan M, Zimmermann S, Markus K, Ruder H, Muller-Wiefel DE. Immune response to non-O157 Vero toxin-producing Escherichia coli in patients with hemolytic uremic syndrome. J Infect Dis 1996;174:1028-39.
12. Bitzan M, Ludwig K, Klemt M, Konig H, Buren J, Muller-Wiefel DE. The role of Escherichia coli O157 infections in the classical (enteropathic) haemolytic uraeraic syndrome: results of a Central European, multicentre study. Epidemiol Infect 1993;110:183-96.
13. Chart H, Smith HR, Scotland SM, Rowe B, Milford DV, Taylor CM. Serological identification of Escherichia coli O157:H7 infection in haemolytic uraemic syndrome. Lancet 1991;337:138-40.
14. Bitzan M, Moebius E, Ludwig K, Muller-Wiefel DE, Heesemann J, Karch H. High incidence of serum antibodies to Escherichia coli O157 lipopolysaccharide in children with hemolytic-uremic syndrome. J Pediatr 1991;119:380-5.